Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform

Allogene Therapeutics, Inc.

Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.
ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.
ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.
Futility analysis on MRD conversion expected in first half 2026.
Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.